Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial

Eva van Doorn, Olga Pleguezuelos, Heng Liu, Ana Fernandez, Robin Bannister, Gregory Stoloff, Fredrik Oftung, Stephen Norley, Anke Huckriede, Henderik W Frijlink, Eelko Hak, Eva van Doorn, Olga Pleguezuelos, Heng Liu, Ana Fernandez, Robin Bannister, Gregory Stoloff, Fredrik Oftung, Stephen Norley, Anke Huckriede, Henderik W Frijlink, Eelko Hak

Abstract

Background: Current influenza vaccines, based on antibodies against surface antigens, are unable to provide protection against newly emerging virus strains which differ from the vaccine strains. Therefore the population has to be re-vaccinated annually. It is thus important to develop vaccines which induce protective immunity to a broad spectrum of influenza viruses. This trial is designed to evaluate the immunogenicity and safety of FLU-v, a vaccine composed of four synthetic peptides with conserved epitopes from influenza A and B strains expected to elicit both cell mediated immunity (CMI) and humoral immunity providing protection against a broad spectrum of influenza viruses.

Methods: In a single-center, randomized, double-blind and placebo-controlled phase IIb trial, 222 healthy volunteers aged 18-60 years will be randomized (2:2:1:1) to receive two injections of a suspension of 500 μg FLU-v in saline (arm 1), one dose of emulsified 500 μg FLU-v in Montanide ISA-51 and water for injection (WFI) followed by one saline dose (arm 2), two saline doses (arm 3), or one dose of Montanide ISA-51 and WFI emulsion followed by one saline dose (arm 4). All injections will be given subcutaneously. Primary endpoints are safety and FLU-v induced CMI, evaluated by cytokine production by antigen specific T cell populations (flow-cytometry and ELISA). Secondary outcomes are measurements of antibody responses (ELISA and multiplex), whereas exploratory outcomes include clinical efficacy and additional CMI assays (ELISpot) to show cross-reactivity.

Discussion: Broadly protective influenza vaccines able to provide protection against multiple strains of influenza are urgently needed. FLU-v is a promising vaccine which has shown to trigger the cell-mediated immune response. The dosages and formulations tested in this current trial are also estimated to induce antibody response. Therefore, both cellular and humoral immune responses will be evaluated.

Trial registration: EudraCT number 2015-001932-38 ; retrospectively registered clinicaltrials.gov NCT02962908 (November 7th 2016).

Keywords: Broadly protection; CMI; Clinical trial; FLU-v; Influenza; Universal; Vaccine.

Figures

Fig. 1
Fig. 1
Flow chart of the study’s design

References

    1. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004;59(1):1–15. doi: 10.1111/j.0300-9475.2004.01382.x.
    1. World Health Organization. Influenza virus infections in humans. 2014. Available at: . Accessed 13 Apr 2015.
    1. World Health Organization. Influenza (Seasonal) Fact sheet Number 211 March 2014.
    1. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121(4):258–264. doi: 10.1016/j.amjmed.2007.10.040.
    1. European Commission. Proposal for a Council Recommendation on seasonal influenza vaccination. 2009. Available at: . Accessed 13 April 2015.
    1. Levy E. French economic evaluations of influenza and influenza vaccination. PharmacoEconomics. 1996;9(Suppl 3):62–66. doi: 10.2165/00019053-199600093-00014.
    1. Lee K, Seong BL. Current status for influenza control. Biotechnol Bioprocess Eng. 1999;4:157–164. doi: 10.1007/BF02931921.
    1. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69:531–569. doi: 10.1146/annurev.biochem.69.1.531.
    1. Shtyrya YA, Mochalova LV, Bovin NV. Influenza virus neuraminidase: structure and function. Acta Nat. 2009;1(2):26–32.
    1. Verhoeyen M, Fang R, Jou WM, Devos R, Huylebroeck D, Saman E, Fiers W. Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75. Nature. 1980;286(5775):771–776. doi: 10.1038/286771a0.
    1. World Health Organization. Questions and answers. Vaccine effectiveness estimates for seasonal influenza vaccines. 2015. Available at: . Accessed 13 April 2015.
    1. Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: Shifting to better vaccines. Vaccine. 2016;34(26):2926–2933. doi: 10.1016/j.vaccine.2016.03.085.
    1. Pleguezuelos O, Robinson S, Stoloff GA, Caparros-Wanderly W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomized, placebo-controlled Phase I trial. Vaccine. 2012;30:4655–4660. doi: 10.1016/j.vaccine.2012.04.089.
    1. Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines. 2013;12(5):519–536. doi: 10.1586/erv.13.35.
    1. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013;19(10):1305–1312. doi: 10.1038/nm.3350.
    1. Altman DG, Bland JM. How to randomise. BMJ. 1999;319(7211):703–704. doi: 10.1136/bmj.319.7211.703.
    1. ALEA. Release version 15.1. Available at: .
    1. Schulz KF, Altman DG, Moher D, CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251. doi: 10.1371/journal.pmed.1000251.
    1. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012;18(2):274–280. doi: 10.1038/nm.2612.
    1. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods. 2007;323(1):39–54. doi: 10.1016/j.jim.2007.03.002.
    1. Salk HM, Haralambieva IH, Ovsyannikova IG, Goergen KM, Poland GA. Granzyme B ELISPOT assay to measure influenza-specific cellular immunity. J Immunol Methods 2013;398-399:44-50.
    1. Lindemann M, Witzke O, Lutkes P, Fiedler M, Kreuzfelder E, Philipp T, et al. ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. Clin Immunol. 2006;120(3):342–348. doi: 10.1016/j.clim.2006.03.002.
    1. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol. 2013;190(4):1837–1848. doi: 10.4049/jimmunol.1201574.
    1. Pleguezuelos O, Robinson S, Fernandez A, Stoloff GA, Mann A, Gilbert A, et al. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans. Clin Vaccine Immunol. 2015;22(7):828–835. doi: 10.1128/CVI.00098-15.
    1. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci. 2009;98(4):1278–1316. doi: 10.1002/jps.21523.
    1. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines. 2002;1(1):111–118. doi: 10.1586/14760584.1.1.111.
    1. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine. 2001;19(17–19):2666–2672. doi: 10.1016/S0264-410X(00)00498-9.
    1. van Doorn E, Liu H, Huckriede A, Hak E. Safety and tolerability evaluation of the use of Montanide ISA51 as vaccine adjuvant: a systematic review. Hum Vaccin Immunother. 2016;12(1):159–169. doi: 10.1080/21645515.2015.1071455.
    1. Ascarateil S, Puget A, Koziol M. Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines. J Immunother Cancer. 2015;3(suppl 2):428. doi: 10.1186/2051-1426-3-S2-P428.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel